Pancreatic Cancer Research

ResearcherUniversity of Electronic Science and Technology of ChinaActive in the last 2 years

Chong Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0060-706X; OpenAlex author ID A5102849149. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 11

  1. Real-time fluorescence-assisted semi-ex vivo intestinal autotransplantation for pancreatic adenocarcinoma patients with mesenteric root invasion (with video). First author DOI 10.1016/j.hbpd.2024.07.003↗
  2. RNF26 Promotes Pancreatic Cancer Proliferation by Enhancing RBM38 Degradation. Last author DOI 10.1097/mpa.0000000000002183↗
  3. Pseudogene AK4P1 promotes pancreatic ductal adenocarcinoma progression through relieving miR-375-mediated YAP1 degradation. Co-author DOI 10.18632/aging.203921↗
  4. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Co-author DOI 10.1016/j.bbadis.2021.166213↗
  5. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. Last author DOI 10.1186/s13046-021-01879-w↗
  6. Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.644156↗
  7. FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression. Co-author PMID 32195024↗
  8. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2019.01.011↗
  9. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. Co-author PMID 31497353↗
  10. 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8367↗
  11. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. First author DOI 10.1074/jbc.m116.764407↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Jin · 7 shared papers, 2017–2021 · strength 0.75
  2. Shikai Zhu · 5 shared papers, 2018–2022 · strength 0.60
  3. Ping Fan · 5 shared papers, 2017–2020 · strength 0.49
  4. Heshui Wu · 4 shared papers, 2017–2021 · strength 0.40
  5. Jingyuan Zhao · 3 shared papers, 2019–2021 · strength 0.35
  6. Wenjie Su · 2 shared papers, 2021 · strength 0.28
  7. Yu Zhang · 1 shared paper, 2025 · strength 0.27
  8. Wan Yee Lau · 1 shared paper, 2025 · strength 0.27
  9. Peng Li · 1 shared paper, 2025 · strength 0.27
  10. Xin-Yu You · 1 shared paper, 2025 · strength 0.27
  11. Dianyun Ren · 2 shared papers, 2021 · strength 0.26
  12. Zibo Meng · 2 shared papers, 2019–2020 · strength 0.21
  13. Xiangyu Lu · 1 shared paper, 2022 · strength 0.16
  14. Haoyuan Ren · 1 shared paper, 2021 · strength 0.16
  15. Yun Zhang · 1 shared paper, 2022 · strength 0.15
  16. Lang Jia · 1 shared paper, 2022 · strength 0.15
  17. Yingke Zhou · 1 shared paper, 2021 · strength 0.14
  18. Yan Sun · 1 shared paper, 2021 · strength 0.14
  19. Qiang Fu · 1 shared paper, 2021 · strength 0.12
  20. Kun Zhang · 1 shared paper, 2020 · strength 0.12
  21. Bo Wang · 1 shared paper, 2019 · strength 0.09
  22. Zhiqiang Liu · 1 shared paper, 2019 · strength 0.09
  23. Shihong Wu · 1 shared paper, 2019 · strength 0.09
  24. Tao Liu · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.